We are live on ! Find out more
PETX

Aratana Therapeutics, Inc.
PETX

Delisted

PETX was delisted on the 17th of July, 2019.

129 hedge funds and large institutions have $268M invested in Aratana Therapeutics, Inc. in 2016 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 42 increasing their positions, 21 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

171% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 17

100% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 21

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

40% more capital invested

Capital invested by funds: $191M → $268M (+$76.8M)

29% more funds holding

Funds holding: 100129 (+29)

18% less call options, than puts

Call options by funds: $178K | Put options by funds: $218K

Holders
129
Holders Change
+29
Holders Change %
+29%
% of All Funds
3.43%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.08%
New
46
Increased
42
Reduced
21
Closed
17
Calls
$178K
Puts
$218K
Net Calls
-$40K
Net Calls Change
-$138K

PETX Hedge Fund Activity: Q3 2016 in Review

129 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Aratana Therapeutics, Inc. (PETX) for Q3 2016, worth a combined $268M — up 40% from $191M a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new PETX positions and 17 closed out — a net gain of 29 holders — while 42 added to existing stakes and 21 trimmed.

The largest buyer was Acadian Asset Management, opening a new position worth an estimated $9.99M. The largest seller was Jennison Associates, cutting an estimated $13.6M.

  • 129 institutional investors held Aratana Therapeutics, Inc. (PETX) as of Q3 2016, up from 100 in Q2 2016.
  • Funds reported $268M of Aratana Therapeutics, Inc. stock for Q3 2016, up 40% quarter-over-quarter.
  • 46 funds opened new Aratana Therapeutics, Inc. positions in Q3 2016 and 17 closed out, a net change of +29 holders.
  • The largest Aratana Therapeutics, Inc. buyer in Q3 2016 was Acadian Asset Management, an estimated $9.99M added.
  • The largest Aratana Therapeutics, Inc. seller in Q3 2016 was Jennison Associates, an estimated $13.6M sold.

Based on aggregated 13F filings for Q3 2016.